A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
暂无分享,去创建一个
J. Bosch-Barrera | R. Rosell | N. Reguart | M. Provencio | R. Palmero | T. Morán | A. Insa | D. Isla | M. Majem | C. Lee | D. Schnell | S. Kraemer | M. Puig | E. C. Costa